Oral STAT6 Degrader BCR-0008 Clears China Clinical Entry
Hangzhou Baicreat reported that China’s NMPA Center for Drug Evaluation permitted clinical testing of BCR-0008, an oral STAT6-targeted PROTAC intended initially for atopic dermatitis and asthma. The milestone moves targeted protein degradation into a…
